Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma

Patients with advanced head and neck squamous cell carcinoma (HNSCC) usually show a dismal prognosis. It is this worthwhile to develop new, effective therapeutic regimens for these patients, such as molecular targeted therapy, which is promising as an alternative or combination treatment for HNSCC....

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Ming-Huei, Chuang, Hui-Ching, Lin, Yu-Tsai, Tsai, Ming-Hsien, Kao, Ying-Hsien, Lin, I-Chun, Huang, Tai-Lin, Fang, Fu-Min, Chien, Chih-Yen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002492/
https://www.ncbi.nlm.nih.gov/pubmed/33802643
http://dx.doi.org/10.3390/ijms22063046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002492/
https://www.ncbi.nlm.nih.gov/pubmed/33802643
http://dx.doi.org/10.3390/ijms22063046

Ejemplares similares